WO2009035020A1 - 新規ジヒドロナフタレン化合物及びその用途 - Google Patents
新規ジヒドロナフタレン化合物及びその用途 Download PDFInfo
- Publication number
- WO2009035020A1 WO2009035020A1 PCT/JP2008/066384 JP2008066384W WO2009035020A1 WO 2009035020 A1 WO2009035020 A1 WO 2009035020A1 JP 2008066384 W JP2008066384 W JP 2008066384W WO 2009035020 A1 WO2009035020 A1 WO 2009035020A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- integer
- atom
- compound
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/24—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system containing rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
ラソフォキシフェンあるいはナフォキシジンに比較し生産効率に優れた化学構造を有するジヒドロナフタレン化合物として以下の式(I)で表される化合物を提供する。この化合物は、プロテアソーム阻害剤及び/又は抗ガン剤として有効である。
(但し、式中、2つの-(CH2)l-N(R1)(R2)基は同一の置換基を表し、R1及びR2は、水素原子、又はそれぞれ同一若しくは異なるアルキル基を表し、R1及びR2は、一緒になってそれらを有する窒素原子とともに、又はさらに酸素原子、硫黄原子、及び窒素原子のいずれか1種以上とともに、単環式複素環を形成してもよい。また、R3、R4、R5は、それぞれ水素原子、アルキル基、アシル基、脂環式基、芳香族基、ハロゲン原子、アシルオキシ基、シアノ基、及びニトロ基から選ばれた1種以上の置換基を表し、lは2~5の整数、nは1~4の整数、mは1~5の整数、qは1~3の整数をそれぞれ表す。)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009532207A JP5565667B2 (ja) | 2007-09-11 | 2008-09-11 | 新規ジヒドロナフタレン化合物及びその用途 |
EP08830489A EP2192108B1 (en) | 2007-09-11 | 2008-09-11 | Novel dihydronaphthalene compound and use thereof |
US12/675,331 US8183235B2 (en) | 2007-09-11 | 2008-09-11 | Dihydronaphthalene compound and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007235933 | 2007-09-11 | ||
JP2007-235933 | 2007-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009035020A1 true WO2009035020A1 (ja) | 2009-03-19 |
Family
ID=40452027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/066384 WO2009035020A1 (ja) | 2007-09-11 | 2008-09-11 | 新規ジヒドロナフタレン化合物及びその用途 |
Country Status (4)
Country | Link |
---|---|
US (1) | US8183235B2 (ja) |
EP (1) | EP2192108B1 (ja) |
JP (2) | JP5565667B2 (ja) |
WO (1) | WO2009035020A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2013165005A1 (ja) * | 2012-05-01 | 2015-12-24 | 学校法人東京理科大学 | 新規化合物及びその製造方法並びに抗がん剤 |
WO2021075147A1 (ja) * | 2019-10-15 | 2021-04-22 | 学校法人東京理科大学 | Brap2作用増強剤 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3092244B1 (en) | 2014-01-10 | 2019-08-14 | Cornell University | Dipeptides as inhibitors of human immunoproteasomes |
CN107073069B (zh) | 2014-08-18 | 2022-03-08 | 康奈尔大学 | 作为人免疫蛋白酶体的抑制剂的二肽模拟物 |
JP6970085B2 (ja) * | 2015-10-15 | 2021-11-24 | コーネル・ユニバーシティーCornell University | プロテアソーム阻害剤およびその用途 |
CN105541662B (zh) * | 2015-12-28 | 2018-04-17 | 云南大学 | 二氢萘类化合物的固相合成方法 |
EP3694605A4 (en) | 2017-10-11 | 2021-10-27 | Cornell University | PEPTIDOMIMETIC PROTEASOME INHIBITORS |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3274213A (en) * | 1961-09-05 | 1966-09-20 | Upjohn Co | Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes |
JP2006117648A (ja) | 2004-09-22 | 2006-05-11 | Tokyo Univ Of Science | タモキシフェン類縁体を有効成分として含有する抗ガン剤 |
JP2007224016A (ja) * | 2006-01-26 | 2007-09-06 | Tokyo Univ Of Science | ラソフォキシフェン及びその類縁体の製造方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1336602A1 (en) * | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases |
JP4066238B2 (ja) * | 2002-06-21 | 2008-03-26 | 学校法人東京理科大学 | タモキシフェン類縁体及びその製造方法 |
JP4572407B2 (ja) * | 2005-03-04 | 2010-11-04 | 学校法人東京理科大学 | ドロロキシフェンの製造方法 |
JP2007246493A (ja) * | 2006-03-20 | 2007-09-27 | Tokyo Univ Of Science | タモキシフェン類縁体を有効成分として含有する血管新生抑制剤 |
JP5207226B2 (ja) * | 2006-09-13 | 2013-06-12 | 学校法人東京理科大学 | タモキシフェン類縁体を有効成分として含有するプロテアソーム阻害剤 |
-
2008
- 2008-09-11 US US12/675,331 patent/US8183235B2/en not_active Expired - Fee Related
- 2008-09-11 JP JP2009532207A patent/JP5565667B2/ja not_active Expired - Fee Related
- 2008-09-11 EP EP08830489A patent/EP2192108B1/en not_active Not-in-force
- 2008-09-11 WO PCT/JP2008/066384 patent/WO2009035020A1/ja active Application Filing
-
2014
- 2014-04-16 JP JP2014084152A patent/JP5747394B2/ja not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3274213A (en) * | 1961-09-05 | 1966-09-20 | Upjohn Co | Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes |
JP2006117648A (ja) | 2004-09-22 | 2006-05-11 | Tokyo Univ Of Science | タモキシフェン類縁体を有効成分として含有する抗ガン剤 |
JP2007224016A (ja) * | 2006-01-26 | 2007-09-06 | Tokyo Univ Of Science | ラソフォキシフェン及びその類縁体の製造方法 |
Non-Patent Citations (3)
Title |
---|
F. L. STEINBAUM; R. L. DE JAGER; I. H. KRAKOFF: "Clinical Trial of Nafoxidine in Advanced Breast Cancer", MEDICAL AND PEDIATRIC ONCOLOGY, vol. 4, 1978, pages 123 - 126 |
HYDER M. SALMAN ET AL.: "Uterine Expression of Vascular Endothelial Growth Factor Is Increased by Estradiol and Tamoxifen1", CANCER RESEARCH, vol. 56, 1996, pages 3954 - 3960, XP008130181 * |
See also references of EP2192108A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2013165005A1 (ja) * | 2012-05-01 | 2015-12-24 | 学校法人東京理科大学 | 新規化合物及びその製造方法並びに抗がん剤 |
WO2021075147A1 (ja) * | 2019-10-15 | 2021-04-22 | 学校法人東京理科大学 | Brap2作用増強剤 |
Also Published As
Publication number | Publication date |
---|---|
EP2192108A4 (en) | 2010-12-01 |
US8183235B2 (en) | 2012-05-22 |
EP2192108B1 (en) | 2013-03-27 |
EP2192108A1 (en) | 2010-06-02 |
JP5747394B2 (ja) | 2015-07-15 |
US20100249400A1 (en) | 2010-09-30 |
JPWO2009035020A1 (ja) | 2010-12-24 |
JP5565667B2 (ja) | 2014-08-06 |
JP2014167005A (ja) | 2014-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009035020A1 (ja) | 新規ジヒドロナフタレン化合物及びその用途 | |
WO2008129912A1 (ja) | フェニル基置換1,3,5-トリアジン化合物、その製造方法、およびこれを構成成分とする有機電界発光素子 | |
EA200701176A1 (ru) | Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их | |
MY169179A (en) | Novel piperidine compound or salt thereof | |
WO2009057811A3 (en) | Heterocyclic compound and pharmaceutical composition thereof | |
TW200612920A (en) | Novel imidazolidine derivatives | |
CR8755A (es) | Derivado de quinolina fusionada y uso del mismo | |
SG162805A1 (en) | Pyrazine derivatives useful as adenosine receptor antagonists | |
TW200736230A (en) | Organic compound, charge transporting material, charge transporting material composition and organic electroluminescent element | |
MX2007005933A (es) | Compuestos de acetamida como fungicidas. | |
TW200722422A (en) | Heterocyclic compound and organic electroluminescent device using the same | |
UA89672C2 (en) | Sulfonylamino(thio)carbonyl compounds | |
WO2008108378A3 (en) | Bicyclic oxomorpholine derivative | |
MX2009010823A (es) | Compuesto de hidrazida y agente controlador de artropodos dañinos que contiene el mismo. | |
MX2010002662A (es) | Aminoquinolonas espirociclicas como inhibidores de gsk-3. | |
WO2008155668A3 (en) | Heteroarylamide pyrimidone compounds | |
RS54120B1 (en) | Pyridinyl-I pyrazinyl-methyloxyaryl derivatives USED AS INHIBITORS OF TYROSINE KINASE TREATMENT (SYK) | |
EA201001087A1 (ru) | Новые дигидроиндолоновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
GB2470170A (en) | Dithienothiophene derivatives | |
WO2008149834A1 (ja) | ピリミドジアゼピノン誘導体 | |
EA201390374A1 (ru) | Гетероциклические соединения для лечения или профилактики расстройств, вызываемых ослабленной нейротрансмиссией серотонина, норэпинефрина или допамина | |
TW200619201A (en) | Process for the preparation of pyrazoles | |
EA200701582A1 (ru) | Замещённые 5-фенилпиримидины i в терапии | |
WO2008038030A3 (en) | Dispiro tetraoxane compounds and their use in the treatment of malaria and/or cancer | |
TW200504086A (en) | Novel bismuth compound, process of producing the same, and process of producing a film |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08830489 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009532207 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12675331 Country of ref document: US Ref document number: 2008830489 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |